Steven L. Chuck

4.3k total citations · 3 hit papers
30 papers, 3.4k citations indexed

About

Steven L. Chuck is a scholar working on Epidemiology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Steven L. Chuck has authored 30 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Epidemiology, 11 papers in Infectious Diseases and 9 papers in Molecular Biology. Recurrent topics in Steven L. Chuck's work include HIV/AIDS drug development and treatment (10 papers), Hepatitis B Virus Studies (9 papers) and Hepatitis C virus research (9 papers). Steven L. Chuck is often cited by papers focused on HIV/AIDS drug development and treatment (10 papers), Hepatitis B Virus Studies (9 papers) and Hepatitis C virus research (9 papers). Steven L. Chuck collaborates with scholars based in United States, France and Spain. Steven L. Chuck's co-authors include Merle A. Sande, Vishwanath R. Lingappa, Sarah Hevi, Andrew Cheng, Jeffrey Enejosa, Sarah Arterburn, Katyna Borroto–Esoda, Edwin DeJesus, Stephanos J. Hadziyannis and Carol Brosgart and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Steven L. Chuck

30 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

2006 703 citations Joel E. Gallant, Edwin DeJesus et al. New England Journal of Medicine profile →
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years

2006 703 citations Stephanos J. Hadziyannis, Nicolaos C. Tassopoulos et al. Gastroenterology profile →
Infections withCryptococcus neoformansin the Acquired Immunodeficiency Syndrome

1989 588 citations Steven L. Chuck, Merle A. Sande New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven L. Chuck United States	22	1.8k	1.6k	981	862	492	30	3.4k
Gianpiero D’Offizi Italy	27	758 0.4×	757 0.5×	640 0.7×	638 0.7×	300 0.6×	127	2.4k
G Scullard United Kingdom	20	914 0.5×	659 0.4×	643 0.7×	471 0.5×	186 0.4×	29	1.8k
Jean‐Pierre Sommadossi United States	35	1.2k 0.7×	2.0k 1.2×	495 0.5×	1.0k 1.2×	1.0k 2.1×	98	3.8k
Andreas Cerny Switzerland	35	2.6k 1.5×	521 0.3×	2.7k 2.8×	473 0.5×	479 1.0×	102	4.7k
André Kirn France	26	611 0.3×	755 0.5×	538 0.5×	452 0.5×	523 1.1×	57	2.0k
Janice A. Kolberg United States	26	2.8k 1.6×	840 0.5×	2.9k 3.0×	581 0.7×	644 1.3×	63	4.3k
Diana M. Brainard United States	50	5.3k 3.0×	2.6k 1.6×	5.7k 5.8×	911 1.1×	318 0.6×	189	7.6k
Charles M. Heldebrant United States	15	522 0.3×	858 0.5×	245 0.2×	913 1.1×	270 0.5×	23	2.0k
Ping An United States	31	755 0.4×	550 0.3×	386 0.4×	750 0.9×	701 1.4×	76	2.5k
Christian Callebaut United States	29	525 0.3×	1.7k 1.0×	225 0.2×	1.5k 1.7×	544 1.1×	96	2.8k

Countries citing papers authored by Steven L. Chuck

Since Specialization

Citations

This map shows the geographic impact of Steven L. Chuck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven L. Chuck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven L. Chuck more than expected).

Fields of papers citing papers by Steven L. Chuck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven L. Chuck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven L. Chuck. The network helps show where Steven L. Chuck may publish in the future.

Co-authorship network of co-authors of Steven L. Chuck

This figure shows the co-authorship network connecting the top 25 collaborators of Steven L. Chuck. A scholar is included among the top collaborators of Steven L. Chuck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven L. Chuck. Steven L. Chuck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sáez‐Llorens, Xavier, Elizabeth Castaño, Mobeen H. Rathore, et al.. (2014). A Randomized, Open-Label Study of the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate in HIV-1–infected Children With Virologic Suppression. The Pediatric Infectious Disease Journal. 34(4). 376–382. 15 indexed citations

Elion, Richard, Jean‐Michel Molina, José Ramón Arribas, et al.. (2013). A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 63(4). 494–497. 33 indexed citations

Negra, Marinella Della, Marcos Tadeu Nolasco da Silva, Jorge Pinto, et al.. (2012). A Randomized Study of Tenofovir Disoproxil Fumarate in Treatment-experienced HIV-1 Infected Adolescents. The Pediatric Infectious Disease Journal. 31(5). 469–473. 22 indexed citations

Elion, Richard, Calvin Cohen, Joseph Gathe, et al.. (2011). Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS. 25(15). 1881–1886. 76 indexed citations

Molina, Jean‐Michel, Anthony LaMarca, Jaime Andrade‐Villanueva, et al.. (2011). Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. The Lancet Infectious Diseases. 12(1). 27–35. 128 indexed citations

Cohen, Calvin, Richard Elion, Peter Ruane, et al.. (2011). Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 25(6). F7–F12. 93 indexed citations

Zolopa, Andrew, Daniel S Berger, Harry Lampiris, et al.. (2010). Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial. The Journal of Infectious Diseases. 201(6). 814–822. 103 indexed citations

Schiff, Eugene R., Ching‐Lung Lai, Stephanos J. Hadziyannis, et al.. (2007). Adefovir Dipivoxil for Wait-Listed and Post–Liver Transplantation Patients with Lamivudine-Resistant Hepatitis B. Liver Transplantation. 13(3). 349–360. 164 indexed citations

Chang, Ting‐Tsung, Myron J. Tong, Piyawat Komolmit, et al.. (2006). Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B. Journal of Hepatology. 44. 7 indexed citations

10.

Hadziyannis, Stephanos J., Nicolaos C. Tassopoulos, E. Jenny Heathcote, et al.. (2006). Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years. Gastroenterology. 131(6). 1743–1751. 703 indexed citations breakdown →

11.

Schiff, Eugene R., Ching‐Lung Lai, P. Neuhaus, et al.. (2006). 2 Safety and efficacy of adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B undergoing liver transplantation. Journal of Hepatology. 44. S3–S3. 4 indexed citations

12.

Gallant, Joel E., Edwin DeJesus, José Ramón Arribas, et al.. (2006). Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV. New England Journal of Medicine. 354(3). 251–260. 703 indexed citations breakdown →

13.

Hevi, Sarah & Steven L. Chuck. (2003). Ferritins Can Regulate the Secretion of Apolipoprotein B. Journal of Biological Chemistry. 278(34). 31924–31929. 31 indexed citations

14.

Ghosh, Sharmistha, Sarah Hevi, & Steven L. Chuck. (2003). Regulated secretion of glycosylated human ferritin from hepatocytes. Blood. 103(6). 2369–2376. 106 indexed citations

15.

Hevi, Sarah, et al.. (2002). A Proteomic Approach Identifies Proteins in Hepatocytes That Bind Nascent Apolipoprotein B. Journal of Biological Chemistry. 277(24). 22010–22017. 44 indexed citations

16.

Chen, Yin, Françoise Le Cahérec, & Steven L. Chuck. (1998). Calnexin and Other Factors That Alter Translocation Affect the Rapid Binding of Ubiquitin to ApoB in the Sec61 Complex. Journal of Biological Chemistry. 273(19). 11887–11894. 82 indexed citations

17.

Chuck, Steven L., Robert M. Grant, Edward Katongole‐Mbidde, Marcus A. Conant, & Don Ganem. (1996). Frequent Presence of a Novel Herpesvirus Genome in Lesions of Human Immunodeficiency Virus-Negative Kaposi's Sarcoma. The Journal of Infectious Diseases. 173(1). 248–251. 68 indexed citations

18.

Chuck, Steven L. & Vishwanath R. Lingappa. (1992). Pause transfer: A topogenic sequence in apolipoprotein B mediates stopping and restarting of translocation. Cell. 68(1). 9–21. 107 indexed citations

19.

Chuck, Steven L., Zemin Yao, Brian D. Blackhart, Brian J. McCarthy, & Vishwanath R. Lingappa. (1990). New variation on the translocation of proteins during early biogenesis of apolipoprotein B. Nature. 346(6282). 382–385. 94 indexed citations

20.

Chuck, Steven L. & Merle A. Sande. (1989). Infections withCryptococcus neoformansin the Acquired Immunodeficiency Syndrome. New England Journal of Medicine. 321(12). 794–799. 588 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact